Literature DB >> 7705708

Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.

T Beck1, E E Weller, W Weikel, C Brumm, C Wilkens, P G Knapstein.   

Abstract

Mutations of the p53 gene often result in the overexpression of p53 protein. Previous studies have suggested that the function of p53 and its mutant protein forms may be linked with the disease course of patients with a breast carcinoma. In the present study, we tested 462 primary breast carcinomas for the presence of p53 antigen using immunohistochemical methods employing antibodies against the clone, DO-1. These tumors were also immunohistochemically stained using the monoclonal antibody, MIB-1, in order to demonstrate the presence of Ki67. Comparison of the presence of p53 with other prognostic parameters revealed highly significant negative correlations with estrogen- and progesterone-receptor status (P < 0.001 and P = 0.001, respectively) as well as positive correlations with both the presence of MIB-1 (P < 0.001) and the histological grading (P = 0.008). The presence of p53 was not correlated with tumor stage and node status. Evaluation of the findings for all 462 tumors as well as for node-positive and -negative subgroups revealed less favorable findings for overall survival and the disease-free period for both p53-positive tumors (for total group, overall survival, P = 0.0002, disease-free period, P = 0.02; for node-positive group, overall survival, P = 0.0004, disease-free period, P = 0.1045) and breast carcinomas with higher proportions of cell nuclei positive for MIB-1 (total, overall survival, P = 0.0026, disease-free period, P = 0.0022; node-positive, overall survival, P = 0.021, disease-free period, P = 0.0882). We were able to demonstrate that p53 expression in breast carcinomas means a significantly worse prognosis for grade II tumors (overall survival, P = 0.0002; disease-free period, P = 0.0116), for overall survival in the case of estrogen-receptor-positive tumors (P = 0.014), and for tumors showing increased proliferation activity (overall survival, P = 0.0477).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7705708     DOI: 10.1006/gyno.1995.1104

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

Review 1.  Proliferation markers in tumours: interpretation and clinical value.

Authors:  P J van Diest; G Brugal; J P Baak
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

2.  p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.

Authors:  T Megha; F Ferrari; A Benvenuto; C Bellan; A V Lalinga; S Lazzi; S Bartolommei; G Cevenini; L Leoncini; P Tosi
Journal:  J Clin Pathol       Date:  2002-06       Impact factor: 3.411

3.  The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer.

Authors:  T Pietiläinen; P Lipponen; S Aaltomaa; M Eskelinen; V M Kosma; K Syrjänen
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  AgNOR quantity in needle biopsy specimens of prostatic adenocarcinomas: correlation with proliferation state, Gleason score, clinical stage, and DNA content.

Authors:  D Trerè; A Zilbering; D Dittus; P Kim; P C Ginsberg; I Daskal
Journal:  Clin Mol Pathol       Date:  1996-08

5.  Prognostic significance of immunohistochemical expression of p53 gene product in operable breast cancer.

Authors:  Hong Suk Song; Young Rok Do; Sun Hee Kang; Ki Yong Jeong; Yu Sa Kim
Journal:  Cancer Res Treat       Date:  2006-12-31       Impact factor: 4.679

6.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

Review 7.  Prognostic value of proliferation in invasive breast cancer: a review.

Authors:  P J van Diest; E van der Wall; J P A Baak
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

Review 8.  Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.

Authors:  Elisabeth Luporsi; Fabrice André; Frédérique Spyratos; Pierre-Marie Martin; Jocelyne Jacquemier; Frédérique Penault-Llorca; Nicole Tubiana-Mathieu; Brigitte Sigal-Zafrani; Laurent Arnould; Anne Gompel; Caroline Egele; Bruno Poulet; Krishna B Clough; Hubert Crouet; Alain Fourquet; Jean-Pierre Lefranc; Carole Mathelin; Nicolas Rouyer; Daniel Serin; Marc Spielmann; Margaret Haugh; Marie-Pierre Chenard; Etienne Brain; Patricia de Cremoux; Jean-Pierre Bellocq
Journal:  Breast Cancer Res Treat       Date:  2011-11-03       Impact factor: 4.872

9.  Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation.

Authors:  R Emig; A Magener; V Ehemann; A Meyer; F Stilgenbauer; M Volkmann; D Wallwiener; H P Sinn
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

10.  BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours.

Authors:  V D'Arcy; N Pore; F Docquier; Z K Abdullaev; I Chernukhin; G-X Kita; S Rai; M Smart; D Farrar; S Pack; V Lobanenkov; E Klenova
Journal:  Br J Cancer       Date:  2008-01-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.